Snacking has historically been one of the most resilient categories in the food industry. Built on habit, convenience, and craving, snacks benefited from frequent consumption and emotional attachment. However, the growing adoption of GLP-1 weight loss drugs is quietly rewriting this equation. As appetite suppression becomes mainstream, consumers are eating less — and spending less — on traditional snacks.
From the lens of a market intelligence firm, this shift marks a structural change rather than a temporary slowdown. Studies show that GLP-1 users significantly reduce intake of processed foods, refined grains, sugary snacks, and fast food. Cravings, once the backbone of snacking demand, are no longer as powerful. This behavioral change is already reflected in declining snack volumes across key markets such as North America.
What do current market insights reveal? Consumers using GLP-1s are prioritizing food that delivers satiety, nutrition, and functional benefits. Smaller portions, higher protein content, and cleaner ingredient profiles are gaining relevance. While indulgent snacks face sharper disruption, they are not disappearing — they must evolve.
For snack brands, the challenge is twofold. First, understanding how appetite suppression alters frequency and basket size. Second, identifying where value can still be created. The future of snacking will hinge on “less but better” offerings rather than volume-led growth.
Companies that rely on robust market insights to track consumption patterns, competitive moves, and emerging product formats will be better positioned to respond. The role of a market intelligence firm becomes critical in helping brands separate noise from signal and redesign portfolios for a world where eating less is becoming the norm.